AAAAAA

   
Results: 1-15 |
Results: 15
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
Authors: Figg, WD Dahut, W Duray, P Hamilton, M Tompkins, A Steinberg, SM Jones, E Premkumar, A Linehan, WM Floeter, MK Chen, CC Dixon, S Kohler, DR Kruger, EA Gubish, E Pluda, JM Reed, E
Citation: Wd. Figg et al., A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer, CLIN CANC R, 7(7), 2001, pp. 1888-1893
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
Authors: Rudek, MA Figg, WD Dyer, V Dahut, W Turner, ML Steinberg, SM Liewehr, DJ Kohler, DR Pluda, JM Reed, E
Citation: Ma. Rudek et al., Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer, J CL ONCOL, 19(2), 2001, pp. 584-592
Reversible sideroblastic anemia associated with the tetracycline analogue COL-3
Authors: Rudek, MA Horne, M Figg, WD Dahut, W Dyer, V Pluda, JM Reed, E
Citation: Ma. Rudek et al., Reversible sideroblastic anemia associated with the tetracycline analogue COL-3, AM J HEMAT, 67(1), 2001, pp. 51-53
A phase I and pharmacologic study of 9-aminocamptothecin administered as a120-h infusion weekly to adult cancer patients
Authors: Thomas, RR Dahut, W Harold, N Grem, JL Monahan, BP Liang, M Band, RA Cottrell, J Llorens, V Smith, JA Corse, W Arbuck, SG Wright, J Chen, AP Hamilton, JM Allegra, CJ Takimoto, CH
Citation: Rr. Thomas et al., A phase I and pharmacologic study of 9-aminocamptothecin administered as a120-h infusion weekly to adult cancer patients, CANC CHEMOT, 48(3), 2001, pp. 215-222
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer
Authors: Bhargava, P Marshall, JL Fried, K Williams, M Lefebvre, P Dahut, W Hanfelt, J Gehan, E Figuera, M Hawkins, MJ Rizvi, NA
Citation: P. Bhargava et al., Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer, CANC CHEMOT, 48(2), 2001, pp. 95-103
Alendronate does not interfere with Tc-99m-methylene diphosphonate bone scanning
Authors: Carrasquillo, JA Whatley, M Dyer, V Figg, WD Dahut, W
Citation: Ja. Carrasquillo et al., Alendronate does not interfere with Tc-99m-methylene diphosphonate bone scanning, J NUCL MED, 42(9), 2001, pp. 1359-1363
Thalidomide neuropathy in patients treated for metastatic prostate cancer
Authors: Molloy, FM Floeter, MK Syed, NA Sandbrink, F Culcea, E Steinberg, SM Dahut, W Pluda, J Kruger, EA Reed, E Figg, WD
Citation: Fm. Molloy et al., Thalidomide neuropathy in patients treated for metastatic prostate cancer, MUSCLE NERV, 24(8), 2001, pp. 1050-1057
Drug-induced lupus associated with COL-3 - Report of 3 cases
Authors: Ghate, JV Turner, ML Rudek, MA Figg, WD Dahut, W Dyer, V Pluda, JM Reed, E
Citation: Jv. Ghate et al., Drug-induced lupus associated with COL-3 - Report of 3 cases, ARCH DERMAT, 137(4), 2001, pp. 471-474
A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors
Authors: Chen, HX Marshall, JL Ness, E Martin, RR Dvorchik, B Rizvi, N Marquis, J McKinlay, M Dahut, W Hawkins, MJ
Citation: Hx. Chen et al., A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors, CLIN CANC R, 6(4), 2000, pp. 1259-1266
Malignant ascites as only manifestation of metastatic prostate cancer
Authors: Saif, MW Figg, WD Hewitt, S Brosky, K Reed, E Dahut, W
Citation: Mw. Saif et al., Malignant ascites as only manifestation of metastatic prostate cancer, PROSTATE C, 2(5-6), 1999, pp. 290-293
A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer
Authors: Bhargava, P Marshall, JL Rizvi, N Dahut, W Yoe, J Figuera, M Phipps, K Ong, VS Kato, A Hawkins, MJ
Citation: P. Bhargava et al., A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer, CLIN CANC R, 5(8), 1999, pp. 1989-1995
A Phase I study of LGD1069 in adults with advanced cancer
Authors: Rizvi, NA Marshall, JL Dahut, W Ness, E Truglia, JA Loewen, G Gill, GM Ulm, EH Geiser, R Jaunakais, D Hawkins, MJ
Citation: Na. Rizvi et al., A Phase I study of LGD1069 in adults with advanced cancer, CLIN CANC R, 5(7), 1999, pp. 1658-1664
Taxanes in hormone-refractory prostate cancer
Authors: Kang, MH Figg, WD Dahut, W
Citation: Mh. Kang et al., Taxanes in hormone-refractory prostate cancer, CANCER PRAC, 7(5), 1999, pp. 270-272
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
Authors: Bubley, GJ Carducci, M Dahut, W Dawson, N Daliani, D Eisenberger, M Figg, WD Freidlin, B Halabi, S Hudes, G Hussain, M Kaplan, R Myers, C Oh, W Petrylak, DP Reed, E Roth, B Sartor, O Scher, H Simons, J Sinibaldi, V Small, EJ Smith, MR Trump, DL Vollmer, R Wilding, G
Citation: Gj. Bubley et al., Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group, J CL ONCOL, 17(11), 1999, pp. 3461-3467
Docetaxel and gemcitabine combinations in non-small cell lung cancer
Authors: Rizvi, NA Spiridonidis, CH Davis, TH Bhargava, P Marshall, JL Dahut, W Figuera, M Hawkins, MJ
Citation: Na. Rizvi et al., Docetaxel and gemcitabine combinations in non-small cell lung cancer, SEMIN ONCOL, 26(5), 1999, pp. 27-31
Risultati: 1-15 |